ABUS
Arbutus Biopharma Corp
4.50$
-2.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -54.0% | -28.6% | +12.7% | -22.4% | +17.6% | +12.1% | +508.8% | -95.1% | +98.7% | +16,943.4% | -99.4% | – | |
| – | +4,659.9% | -12.3% | -97.7% | – | – | +1.7% | -99.9% | +0.0% | +0.0% | +0.0% | – | – | |
| – | -431.0% | – | +12.7% | -22.4% | -640.4% | – | – | -95.2% | +100.8% | +17,122.6% | -99.4% | – | |
| – | -12.9% | -12.3% | +1.0% | -8.2% | -38.3% | +1.7% | -38.6% | +5.1% | -13.4% | -17.7% | -29.7% | – | |
| – | -12.7% | +4.1% | +42.1% | -39.9% | +85.8% | -30.8% | -42.9% | -8.5% | +21.2% | +59.3% | -34.2% | – | |
| – | -79.7% | +292.2% | +11.6% | -2.3% | -70.6% | +310.1% | -66.3% | -4.8% | -1.4% | +15.1% | -30.2% | – | |
| – | – | – | – | – | – | – | – | -657.3% | – | – | -103.5% | – | |
| – | -4.3% | +0.0% | -22.7% | -14.7% | +3.4% | -6.7% | +0.0% | -17.9% | -21.7% | -5.6% | +5.9% | – | |
| – | – | – | – | – | – | – | – | -406.9% | – | – | -103.0% | – | |
| – | – | -100.0% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | -406.9% | – | – | -103.0% | – | |
| – | – | – | – | – | – | – | – | -400.9% | – | – | -103.0% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.